Publications in collaboration with researchers from Medical University of Vienna (19)

2024

  1. Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma

    American Journal of Hematology

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline

    Annals of Oncology, Vol. 34, Núm. 5, pp. 452-467

2022

  1. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

    The Lancet Oncology, Vol. 23, Núm. 7, pp. e334-e347

  2. EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer

    HemaSphere, Vol. 6, Núm. 8

  3. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

    ESMO Open, Vol. 7, Núm. 2

  4. Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid Tumors

    Thrombosis and Haemostasis, Vol. 122, Núm. 9, pp. 1594-1602

  5. Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry

    Viruses, Vol. 14, Núm. 2

2021

  1. Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism

    European Respiratory Journal, Vol. 58, Núm. 1

2020

  1. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

    Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1850-1859

  2. Single-Cell RNA Sequencing Analysis Reveals a Crucial Role for CTHRC1 (Collagen Triple Helix Repeat Containing 1) Cardiac Fibroblasts After Myocardial Infarction

    Circulation, Vol. 142, Núm. 19, pp. 1831-1847

2019

  1. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

    The Lancet Oncology, Vol. 20, Núm. 10, pp. e566-e581

2017

  1. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

    Leukemia, Vol. 31, Núm. 1, pp. 107-114

  2. Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH

    Journal of Thrombosis and Haemostasis, Vol. 15, Núm. 10, pp. 2076-2079

2015

  1. The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry

    Thrombosis Journal, Vol. 13, Núm. 1

2013

  1. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer

    Journal of Thrombosis and Haemostasis, Vol. 11, Núm. 1, pp. 71-80

  2. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

    Journal of Thrombosis and Haemostasis, Vol. 11, Núm. 1, pp. 56-70

2008

  1. Lenalidomide: A new therapy for multiple myeloma

    Cancer Treatment Reviews, Vol. 34, Núm. 3, pp. 283-291

2007

  1. The emerging role of targeted therapy for hematologic malignancies: Update on bortezomib and tipifarnib

    Oncologist, Vol. 12, Núm. 3, pp. 281-290